Patents by Inventor Seung Kook Park
Seung Kook Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141103Abstract: The present disclosure relates to a method for preparing a polyalkylene carbonate resin, and more particularly, to a method for preparing a polyalkylene carbonate resin having the reduced cyclic carbonate content, which is a by-product, and an increased ratio of a repeating unit including carbon dioxide, by increasing catalyst activity.Type: ApplicationFiled: September 26, 2022Publication date: May 2, 2024Inventors: Seung Hee LEE, Sang Kook KIM, Sang Woo KIM, Bo Ra SHIN, No Jin PARK
-
Publication number: 20240130109Abstract: A semiconductor device includes: a semiconductor device, comprising: a bit line structure including a bit line contact plug, a bit line, and a bit line hard mask that are sequentially stacked over a substrate; a storage node contact plug that is spaced apart from the bit line structure; a conformal spacer that is positioned between the bit line and the storage node contact plug and includes a low-k material; and a seed liner that is positioned between the conformal spacer and the bit line and thinner than the conformal spacer.Type: ApplicationFiled: December 15, 2023Publication date: April 18, 2024Inventors: Beom Ho MUN, Eun Jeong KIM, Jong Kook PARK, Seung Mi LEE, Ji Won CHOI, Kyoung Tak KIM, Yun Hyuck JI
-
Publication number: 20240092913Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: November 17, 2023Publication date: March 21, 2024Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
-
Publication number: 20240059768Abstract: The present invention relates to a stable ophthalmic composition comprising tanfanercept, which does not use a stabilizer, and methods of preparing and using the composition. According to the present invention, it was found that the use of a stabilizer such as histidine or sucrose causes the generation of impurities such as tanfanercept-derived acidic/basic variants, and affects biological activity. The ophthalmic pharmaceutical composition according to the present invention may control pH rather than excluding the use of such a stabilizer to significantly reduce the generation of impurities under not only a refrigerated storage condition but also accelerated conditions and a stress condition, thereby preparing a stable tanfanercept ophthalmic composition.Type: ApplicationFiled: January 13, 2022Publication date: February 22, 2024Inventors: Seung Kook Park, Hyea Kyung Ahn, Mi Jin Jung, Hye Eun Shim
-
Publication number: 20240059767Abstract: The present invention relates to treatment of dry eye syndrome using a tanfanercept-containing ophthalmic composition. According to the present invention, as a result of clinical trial on dry eye syndrome, the tanfanercept-containing ophthalmic composition demonstrated excellent effects with regard to improvement of a central corneal staining score (CCSS) and a total corneal staining score (TCSS), which is clinically important. Further, such improvement of a central corneal staining score (CCSS) and a total corneal staining score (TCSS) was more significantly demonstrated in the patients with moderate-to-severe severity of dry eye. In addition, the patients with higher ocular discomfort score or higher eye dryness score, which are subjective symptoms, also showed greater improvement. Even though the same dose of tanfanercept was used, the tanfanercept-containing ophthalmic composition showed superior efficacy in the patient having more serious or severe baseline sign or symptom scores.Type: ApplicationFiled: January 14, 2021Publication date: February 22, 2024Inventors: Seung Kook Park, Hyea Kyung Ahn, Hye Eun Shim, Young Ju Kim, Sun Mi Park, Joo Hyun Chae
-
Patent number: 11862355Abstract: The present disclosure relates to a method of removing a radioactive structure from a nuclear power plant. The method includes flattening at least a portion of an outer surface of a drilling portion of a wall of a nuclear reactor vessel when the portion of the outer surface is uneven, wherein the radioactive structure is buried in the wall and the drilling portion is adjacent to the radioactive structure, installing a drilling device in the flattened drilling portion and performing a drilling operation, extracting the radioactive structure from the wall, and cutting the extracted radioactive structure and storing pieces of the cut radioactive structure in a shielding container.Type: GrantFiled: May 22, 2019Date of Patent: January 2, 2024Assignee: KOREA ATOMIC ENERGY RESEARCH INSTITUTEInventors: Kwanseong Jeong, Seung-Kook Park, Inhye Hahm, Jae Hyun Ha, Sang Bum Hong, Bum Kyoung Seo
-
Publication number: 20230235063Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: February 21, 2023Publication date: July 27, 2023Applicant: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Patent number: 11613578Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: GrantFiled: December 11, 2019Date of Patent: March 28, 2023Assignee: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Publication number: 20210296017Abstract: The present disclosure relates to a method of removing a nuclear power plant activation structure. Specifically, an embodiment of the present disclosure may provide a method of removing a nuclear power plant activation structure including flattening at least a portion of a wall surface of a peripheral portion of a wall of a nuclear reactor, the wall including a buried portion in which a nuclear power plant activation structure is buried and the peripheral portion circumferentially surrounding the buried portion; installing a drilling device in the flattened peripheral portion and performing a drilling operation; removing the nuclear power plant activation structure from the buried portion; and cutting the removed nuclear power plant activation structure and storing pieces of the cut nuclear power plant activation structure in a shielding container.Type: ApplicationFiled: May 22, 2019Publication date: September 23, 2021Applicant: KOREA ATOMIC ENERGY RESEARCH INSTITUTEInventors: Kwanseong JEONG, Seung-Kook PARK, Inhye HAHM, Jae Hyun HA, Sang Bum HONG, Bum Kyoung SEO
-
Patent number: 10933154Abstract: Disclosed are an aroma diffusion module and an aroma diffusion container including the same. The aroma diffusion container according to an embodiment of the present invention includes a container body; an opening and closing unit coupled to the upper end of the container body; and an aroma diffusion module mounted in the container body, in which the aroma diffusion module includes a porous module body; a first hollow formed at one side of the module body; and a second hollow formed inside the module body, a porous aroma diffusion medium is accommodated in the first hollow, and the second hollow allows external air to be introduced into the container body through a slit of a membrane member unit.Type: GrantFiled: May 26, 2017Date of Patent: March 2, 2021Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITYInventor: Seung-Kook Park
-
Publication number: 20200242558Abstract: There is provided a method for decommissioning plan of nuclear facility includes receiving a plurality of decommissioning related information data, and determining whether error data is included in the plurality of decommissioning related information data based on a database which contains characteristic information and decommissioning plan information of a plurality of nuclear facilities. The method further includes analyzing a state of a decommissioning target facility by identifying the decommissioning target facility based on the plurality of decommissioning related information data and the database, wherein when the error data is included in the plurality of decommissioning related information data, said analyzing is performed by identifying the decommissioning target facility based on the plurality of decommissioning related information data from which the error data is excluded and the database.Type: ApplicationFiled: January 16, 2020Publication date: July 30, 2020Inventors: KwanSeong JEONG, Seung-Kook PARK, Inhye HAHM, Jea Hyun HA, SuJung MIN, Sang Bum HONG, Bum Kyoung SEO
-
Patent number: 10665358Abstract: A radioactive waste container, for storing and transporting a radioactive waste, includes a container body, a cover and a water drain unit. The cover is fastened to the container body. The water drain unit is provided at the container body without protruding to an outside of the container body and configured to selectively drain water in the container body.Type: GrantFiled: September 19, 2018Date of Patent: May 26, 2020Assignee: KOREA ATOMIC ENERGY RESEARCH INSTITUTEInventors: KwanSeong Jeong, Jea Hyun Ha, Seung-Kook Park, Bum Kyoung Seo, Sang Bum Hong
-
Publication number: 20200109201Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: December 11, 2019Publication date: April 9, 2020Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
-
Patent number: 10544226Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: GrantFiled: April 30, 2015Date of Patent: January 28, 2020Assignee: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Publication number: 20190304614Abstract: A radioactive waste container, for storing and transporting a radioactive waste, includes a container body, a cover and a water drain unit. The cover is fastened to the container body. The water drain unit is provided at the container body without protruding to an outside of the container body and configured to selectively drain water in the container body.Type: ApplicationFiled: September 19, 2018Publication date: October 3, 2019Inventors: KwanSeong JEONG, Jea Hyun HA, Seung-Kook PARK, Bum Kyoung SEO, Sang Bum HONG
-
Patent number: 10336825Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: GrantFiled: April 5, 2017Date of Patent: July 2, 2019Assignee: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
-
Publication number: 20190135917Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: January 15, 2019Publication date: May 9, 2019Inventors: Sung Wuk KIM, Seung Kook PARK, Jae Kap JEONG, Hyea Kyung AHN, Min Sun KIM, Eun Sun KIM, Hae-Young YONG, Dongok SHIN, Yeon Jung SONG, Tae Hyoung YOO
-
Patent number: 10280207Abstract: The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: GrantFiled: June 20, 2014Date of Patent: May 7, 2019Assignee: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Min Sun Kim, Eun Sun Kim, Jeong Haing Heo, Yeon Jung Song, Hae-Young Yong, Dongok Shin
-
Publication number: 20190111171Abstract: Disclosed are an aroma diffusion module and an aroma diffusion container including the same. The aroma diffusion container according to an embodiment of the present invention includes a container body; an opening and closing unit coupled to the upper end of the container body; and an aroma diffusion module mounted in the container body, in which the aroma diffusion module includes a porous module body; a first hollow formed at one side of the module body; and a second hollow formed inside the module body, a porous aroma diffusion medium is accommodated in the first hollow, and the second hollow allows external air to be introduced into the container body through a slit of a membrane member unit.Type: ApplicationFiled: May 26, 2017Publication date: April 18, 2019Inventor: Seung-Kook PARK
-
Publication number: 20170210805Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.Type: ApplicationFiled: April 5, 2017Publication date: July 27, 2017Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo